Brief: Aura Biosciences Receives FDA Fast Track Designation For Treatment Of Non-Muscle Invasive Bladder Cancer
30/06/2022 12:22
June 30 (Reuters) - Aura Biosciences Inc AURA.O :
* AURA BIOSCIENCES RECEIVES FDA FAST TRACK DESIGNATION FOR
BELZUPACAP SAROTALOCAN (AU-011) FOR THE TREATMENT OF NON-MUSCLE
INVASIVE BLADDER CANCER
* AURA BIOSCIENCES INC - EXPECTS TO INITIATE TRIAL IN SECOND
HALF
OF 2022, WITH INITIAL PHASE 1 DATA EXPECTED IN 2023
Source text for Eikon: ID:nBw6YRM0Xa
Further company coverage: AURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs